Many Americans are taking GLP1 medications, which include weight loss and diabetes medications Ozempic and Wegovy.

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Come May 22, compounding pharmacies must stop making semaglutide injections, which serve as a more affordable generic ...

Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...

The decision came in response to a February lawsuit from a compounding industry group against the FDA's decision that there ...

Leading dentist Dr Sofina Ahmed shares how GLP-1 medications are creating visible and lasting changes to smiles ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

Compounding pharmacies will no longer be allowed to create semaglutide injections, a generic and cheaper version of Ozempic and Wegovy. This comes after a judge rejected a bid by these pharmacies to ...

According to Healthline, going cold turkey on semaglutide can lead to a an 'internal imbalance' known as a withdrawal. "When ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.